Intractable & Rare Diseases Research
Online ISSN : 2186-361X
Print ISSN : 2186-3644
ISSN-L : 2186-3644
Brief Reports
In vivo quantification of amyloid burden in TTR-related cardiac amyloidosis
Alexander Marco KollikowskiFlorian KahlesSvetlana KintslerSandra HamadaSebastian ReithRuth KnüchelChristoph RöckenFelix Manuel MottaghyNikolaus MarxMathias Burgmaier
Author information

2017 Volume 6 Issue 4 Pages 291-294


Cardiac transthyretin-related (ATTR) amyloidosis is a severe cardiomyopathy for which therapeutic approaches are currently under development. Because non-invasive imaging techniques such as cardiac magnetic resonance imaging and echocardiography are non-specific, the diagnosis of ATTR amyloidosis is still based on myocardial biopsy. Thus, diagnosis of ATTR amyloidosis is difficult in patients refusing myocardial biopsy. Furthermore, myocardial biopsy does not allow 3D-mapping and quantification of myocardial ATTR amyloid. In this report we describe a 99mTc-DPD-based molecular imaging technique for non-invasive single-step diagnosis, three-dimensional mapping and semiquantification of cardiac ATTR amyloidosis in a patient with suspected amyloid heart disease who initially rejected myocardial biopsy. This report underlines the clinical value of SPECT-based nuclear medicine imaging to enable non-invasive diagnosis of cardiac ATTR amyloidosis, particularly in patients rejecting biopsy.

Information related to the author
© 2017 International Research and Cooperation Association for Bio & Socio-Sciences Advancement
Previous article Next article